

Dieter Buchheidt

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4514412/publications.pdf>

Version: 2024-02-01

48
papers

1,977
citations

257450

24
h-index

254184

43
g-index

49
all docs

49
docs citations

49
times ranked

2173
citing authors

#	ARTICLE	IF	CITATIONS
1	Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). <i>Annals of Hematology</i> , 2018, 97, 197-207.	1.8	162
2	Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology. <i>Haematologica</i> , 2009, 94, 113-122.	3.5	160
3	Treatment of invasive fungal infections in cancer patientsâ€”updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). <i>Annals of Hematology</i> , 2014, 93, 13-32.	1.8	143
4	cyp51A-Based Mechanisms of <i>Aspergillus fumigatus</i> Azole Drug Resistance Present in Clinical Samples from Germany. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 3513-3517.	3.2	117
5	Primary prophylaxis of invasive fungal infections in patients with haematologic malignancies. 2014 update of the recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology. <i>Annals of Hematology</i> , 2014, 93, 1449-1456.	1.8	88
6	Molecular Tools for the Detection and Deduction of Azole Antifungal Drug Resistance Phenotypes in <i>Aspergillus</i> Species. <i>Clinical Microbiology Reviews</i> , 2017, 30, 1065-1091.	13.6	86
7	Therapy with antifungals decreases the diagnostic performance of PCR for diagnosing invasive aspergillosis in bronchoalveolar lavage samples of patients with haematological malignancies. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 2260-2267.	3.0	85
8	Diagnosis of invasive aspergillosis in hematological malignancy patients: Performance of cytokines, Asp LFD, and <i>Aspergillus</i> PCR in same day blood and bronchoalveolar lavage samples. <i>Journal of Infection</i> , 2018, 77, 235-241.	3.3	78
9	Spotlight on isavuconazole in the treatment of invasive aspergillosis and mucormycosis: design, development, and place in therapy. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 1033-1044.	4.3	75
10	Influence of mould-active antifungal treatment on the performance of the <i>Aspergillus</i> -specific bronchoalveolar lavage fluid lateral-flow device test. <i>International Journal of Antimicrobial Agents</i> , 2015, 46, 401-405.	2.5	73
11	Epidemiology of invasive aspergillosis and azole resistance in patients with acute leukaemia: the SEPIA Study. <i>International Journal of Antimicrobial Agents</i> , 2017, 49, 218-223.	2.5	71
12	Diagnosis of invasive fungal diseases in haematology and oncology: 2018 update of the recommendations of the infectious diseases working party of the German society for hematology and medical oncology (<sc>AGIHO</sc>). <i>Mycoses</i> , 2018, 61, 796-813.	4.0	69
13	Multicenter evaluation of a lateral-flow device test for diagnosing invasive pulmonary aspergillosis in ICU patients. <i>Critical Care</i> , 2015, 19, 178.	5.8	65
14	Galactomannan testing and <i>Aspergillus</i> PCR in same-day bronchoalveolar lavage and blood samples for diagnosis of invasive aspergillosis. <i>Medical Mycology</i> , 2017, 55, myw102.	0.7	65
15	Central venous catheterâ€”related infections in hematology and oncology: 2020 updated guidelines on diagnosis, management, and prevention by the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). <i>Annals of Hematology</i> , 2021, 100, 239-259.	1.8	54
16	Development of Novel PCR Assays To Detect Azole Resistance-Mediating Mutations of the <i>Aspergillus fumigatus</i> cyp51A Gene in Primary Clinical Samples from Neutropenic Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 3905-3910.	3.2	53
17	Performance of the Bronchoalveolar Lavage Fluid <i>Aspergillus</i> Galactomannan Lateral Flow Assay With Cube Reader for Diagnosis of Invasive Pulmonary Aspergillosis: A Multicenter Cohort Study. <i>Clinical Infectious Diseases</i> , 2021, 73, e1737-e1744.	5.8	48
18	Incidence of Cyp51 A Key Mutations in <i>Aspergillus fumigatus</i> â€”A Study on Primary Clinical Samples of Immunocompromised Patients in the Period of 1995â€”2013. <i>PLoS ONE</i> , 2014, 9, e103113.	2.5	44

#	ARTICLE	IF	CITATIONS
19	Treatment of invasive fungal diseases in cancer patientsâ€”Revised 2019 Recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). <i>Mycoses</i> , 2020, 63, 653-682.	4.0	42
20	Prophylaxis, diagnosis and therapy of infections in patients undergoing high-dose chemotherapy and autologous haematopoietic stem cell transplantation. 2020 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). <i>Annals of Hematology</i> , 2021, 100, 321-336.	1.8	34
21	Management of infections during intensive treatment of hematologic malignancies. <i>Annals of Hematology</i> , 1997, 75, 9-16.	1.8	33
22	<i>Aspergillus</i> PCR testing: results from a prospective PCR study within the AmbiLoad trial. <i>European Journal of Haematology</i> , 2010, 85, 164-169.	2.2	33
23	End-of-life decisions in acute stroke patients: an observational cohort study. <i>BMC Palliative Care</i> , 2016, 15, 38.	1.8	33
24	Risk of Infectious Complications in Hemato-Oncological Patients Treated with Kinase Inhibitors. <i>Biomarker Insights</i> , 2015, 10s3, BMI.S22430.	2.5	29
25	Education in End-of-Life Care: What Do Experienced Professionals Find Important?. <i>Journal of Cancer Education</i> , 2016, 31, 272-278.	1.3	26
26	Direct comparison of galactomannan performance in concurrent serum and bronchoalveolar lavage samples in immunocompromised patients at risk for invasive pulmonary aspergillosis. <i>Mycoses</i> , 2016, 59, 80-85.	4.0	22
27	Comparison of Two Molecular Assays for Detection and Characterization of <i>Aspergillus fumigatus</i> Triazole Resistance and Cyp51A Mutations in Clinical Isolates and Primary Clinical Samples of Immunocompromised Patients. <i>Frontiers in Microbiology</i> , 2018, 9, 555.	3.5	21
28	(New) Methods for Detection of <i>Aspergillus fumigatus</i> Resistance in Clinical Samples. <i>Current Fungal Infection Reports</i> , 2019, 13, 129-136.	2.6	20
29	Clinical evidence for caspofungin monotherapy in the firstâ€”line and salvage therapy of invasive <i>Aspergillus</i> infections. <i>Mycoses</i> , 2016, 59, 480-493.	4.0	19
30	Biomarkerâ€”based diagnostic workâ€”up of invasive pulmonary aspergillosis in immunocompromised paediatric patients â€” is <i>Aspergillus</i> PCR appropriate?. <i>Mycoses</i> , 2016, 59, 67-74.	4.0	16
31	The evolving landscape of new diagnostic tests for invasive aspergillosis in hematology patients. <i>Current Opinion in Infectious Diseases</i> , 2017, 30, 539-544.	3.1	16
32	FunResDBâ€”A web resource for genotypic susceptibility testing of <i>Aspergillus fumigatus</i> . <i>Medical Mycology</i> , 2018, 56, 117-120.	0.7	16
33	Diagnostic work up to assess early response indicators in invasive pulmonary aspergillosis in adult patients with haematologic malignancies. <i>Mycoses</i> , 2019, 62, 486-493.	4.0	16
34	Evaluating the use of PCR for diagnosing invasive aspergillosis. <i>Expert Review of Molecular Diagnostics</i> , 2017, 17, 603-610.	3.1	14
35	Immune Parameters for Diagnosis and Treatment Monitoring in Invasive Mold Infection. <i>Journal of Fungi</i> (Basel, Switzerland), 2019, 5, 116.	3.5	12
36	Progressive Dispersion of Azole Resistance in <i>Aspergillus fumigatus</i> : Fatal Invasive Aspergillosis in a Patient with Acute Myeloid Leukemia Infected with an <i>A. fumigatus</i> Strain with a <i>cyp51A</i> TR₄₆ Y121F M172I T289A Allele. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	10

#	ARTICLE	IF	CITATIONS
37	The risk of infections in hematologic patients treated with rituximab is not influenced by cumulative rituximab dosage - a single center experience. <i>BMC Infectious Diseases</i> , 2014, 14, 364.	2.9	9
38	Aspergillus-specific nested PCR from the site of infection is superior to testing concurrent blood samples in immunocompromised patients with suspected invasive aspergillosis. <i>Mycoses</i> , 2019, 62, 1035-1042.	4.0	7
39	Functional protease profiling for laboratory based diagnosis of invasive aspergillosis. <i>International Journal of Oncology</i> , 2015, 47, 143-150.	3.3	5
40	Molecular diagnosis of invasive aspergillosis in patients with hematologic malignancies – new answers to a diagnostic challenge?. <i>Expert Opinion on Medical Diagnostics</i> , 2008, 2, 753-761.	1.6	4
41	2567. Diagnosis of Invasive Aspergillosis in Hematological Malignancy Patients Receiving Mold-Active Antifungals: Performance of Interleukin-6 and -8, Asp LFD, and Aspergillus PCR in Same-day Blood and Bronchoalveolar Lavage Fluid Samples. <i>Open Forum Infectious Diseases</i> , 2018, 5, S73-S73.	0.9	2
42	Galactomannan-Based and PCR-Based Assays in Bronchoalveolar Lavage to Diagnose Invasive Aspergillosis: Current Status and Future Prospects. <i>Current Fungal Infection Reports</i> , 2013, 7, 273-282.	2.6	1
43	Reply to Mikulska et al. <i>Clinical Infectious Diseases</i> , 2020, 73, e1784-e1785.	5.8	1
44	Galactomannan Testing and Aspergillus PCR in Same-Day Bronchoalveolar Lavage and Blood Samples for Diagnosis of Invasive Mold Infections. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.9	0
45	2268. Clinical Implications of Azole-Resistant vs. Azole-Susceptible Invasive Aspergillosis in Hematological Malignancy (CLARITY): A Multicenter Study. <i>Open Forum Infectious Diseases</i> , 2019, 6, S776-S776.	0.9	0
46	State of Medical Mycology at German Academic Medical Centres: A Survey of the German-Speaking Mycological Society (DMYKG) and the Paul Ehrlich Society for Chemotherapy (PEG). <i>Mycoses</i> , 2021, 64, 1177-1182.	4.0	0
47	Whole Genome Sequencing of Azole-Resistant <i>Aspergillus Fumigatus</i> Strains from Hematopoietic Stem Cell Recipients Identifies Candidate Molecular Targets Potentially Implicated in Novel Resistance Mediating Mechanisms - First Results. <i>Blood</i> , 2015, 126, 4325-4325.	1.4	0
48	Aspergillus Specific PCR and Galactomannan of Bronchoalveolar Lavage Are Superior to Concomitant Same-Day Testing of Concurrent Blood Samples in Immunocompromised Hematological Patients with Suspected Invasive Aspergillosis. <i>Blood</i> , 2015, 126, 2072-2072.	1.4	0